Evidence map›Paper›PMID 34850915›Full record

ArticleThe Journal of clinical endocrinology and metabolism2022

Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival.

Victor Srougi, Irina Bancos, Marilyne Daher, Jeffrey E Lee, Paul H Graham, Jose A Karam, Andres Henriquez, Travis J Mckenzie, Alaa Sada, Isabelle Bourdeau and 12 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Clinicopathological characteristics of adrenocortical carcinoma in the Kyushu-Okinawa area of Japan.International journal of urology : official journal of the Japanese Urological Association · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 4 countries.

Victor SrougiDivision of Urology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0001-8346-3833
Irina BancosDivision of Endocrinology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-9332-2524
Marilyne DaherDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeffrey E LeeDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paul H GrahamDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jose A KaramDepartment of Urology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andres HenriquezDivision of Endocrinology, Mayo Clinic, Rochester, MN, USA.
Travis J MckenzieDivision of Endocrinology, Mayo Clinic, Rochester, MN, USA.
Alaa SadaDivision of Endocrinology, Mayo Clinic, Rochester, MN, USA.
Isabelle BourdeauDivision of Endocrinology and Research Center, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada.
Jonathan PoirierDivision of Endocrinology and Research Center, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada.
Anand VaidyaCenter for Adrenal Disorders, Division of Endocrinology Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Tiffany AbbondanzaCenter for Adrenal Disorders, Division of Endocrinology Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Colleen M KiernanDivision of Surgical Oncology and Endocrine Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Sarika N RaoDivision of Endocrinology, Mayo Clinic, Jacksonville, FL, USA.
Oksana HamidiDivision of Endocrinology and Metabolism, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-7367-3885
Nirupa SachithanandanDepartment of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Melbourne, Australia.
Ana O HoffUnidade de Suprarrenal, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Jose L ChamboDivision of Urology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Madson Q AlmeidaUnidade de Suprarrenal, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Mouhammed Amir HabraDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maria C B V FragosoUnidade de Suprarrenal, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
The University of Texas MD Anderson Cancer Center · USMayo Clinic in Arizona · USHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRBrigham and Women's Hospital · USCentre Hospitalier de l’Université de Montréal · CAUniversidade de São Paulo · BRMayo Clinic in Florida · USSt Vincent's Hospital Melbourne · AUThe University of Texas Southwestern Medical Center · USVanderbilt University Medical Center · US

Funding

Skeletal Consequences of Mild Autonomous Cortisol SecretionK23DK121888 · NIDDK · MAYO CLINIC ROCHESTER · PI BANCOS, IRINA · 2019 to 2022
$630k
NIDDK NIH HHS K23 DK121888
6 · The paper itself

Abstract

contextThe role of cytoreduction of adrenocortical carcinoma (ACC) remains poorly understood.

objectiveTo analyze the impact of cytoreductive surgery of the primary tumor in patients with metastatic ACC. DESIGN AND

settingWe performed a multicentric, retrospective paired cohort study comparing the overall survival (OS) in patients with metastatic ACC who were treated either with cytoreductive surgery (CR group) or without cytoreductive surgery (no-CR group) of the primary tumor. Data were retrieved from 9 referral centers in the American-Australian-Asian Adrenal Alliance collaborative research group. PATIENTS: Patients aged ≥18 years with metastatic ACC at initial presentation who were treated between January 1, 1995, and May 31, 2019.

interventionPerformance (or not) of cytoreductive surgery of the primary tumor. MAIN OUTCOME AND MEASURES: A propensity score match was done using age and the number of organs with metastasis (≤2 or >2). The main outcome was OS, determined from the date of diagnosis until death or until last follow-up for living patients.

resultsOf 339 patients pooled, 239 were paired and included: 128 in the CR group and 111 in the no-CR group. The mean follow-up was 67 months. Patients in the no-CR group had greater risk of death than did patients in the CR group (hazard ratio [HR] = 3.18; 95% CI, 2.34-4.32). Independent predictors of survival included age (HR = 1.02; 95% CI, 1.00-1.03), hormone excess (HR = 2.56; 95% CI, 1.66-3.92), and local metastasis therapy (HR = 0.41; 95% CI, 0.47-0.65).

conclusionCytoreductive surgery of the primary tumor in patients with metastatic ACC is associated with prolonged survival.

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaAdolescentAdultAustraliaCohort StudiesCytoreduction Surgical ProceduresHumansRetrospective Studiesadrenocortical carcinomacytoreduction surgical proceduressurgerysurvival

Identifiers

PMID34850915
PMCPMC9122637
OpenAlexW3215390235

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.